Phase 3 Recruiting Network
This trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. All patients must be receiving trastuzumab-based treatment. Both cohorts are bei…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03418961
Sites in Maryland: - UM Upper Chesapeake Medical Center — Bel Air, Maryland
Phase 3 Recruiting Academic/Other
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…
Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in Maryland: - Maryland Proton Treatment Center — Baltimore, Maryland
- University of Maryland/Greenebaum Cancer Center — Baltimore, Maryland
- Sinai Hospital of Baltimore — Baltimore, Maryland
- UM Upper Chesapeake Medical Center — Bel Air, Maryland
- Central Maryland Radiation Oncology in Howard County — Columbia, Maryland
Phase 3 Recruiting Network
This phase III trial tests two hypotheses in patients with low-risk and average-risk medulloblastoma. Medulloblastoma is a type of cancer that occurs in the back of the brain. The term, risk, refers to the chance of the cancer coming back …
Sponsor: Children's Oncology Group
NCT ID: NCT05382338
Sites in Maryland: - Sinai Hospital of Baltimore — Baltimore, Maryland
- Johns Hopkins University/Sidney Kimmel Cancer Center — Baltimore, Maryland
Phase 3 Recruiting Network
Stereotactic radiosurgery (SRS) is a commonly used treatment for brain tumors. It is a one-day (or in some cases two day), out-patient procedure during which a high dose of radiation is delivered to small spots in the brain while excluding…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT03550391
Sites in Maryland: - Luminis Health Anne Arundel Medical Center — Annapolis, Maryland
- Walter Reed National Military Medical Center — Bethesda, Maryland
Phase 3 Recruiting Industry
This is a randomized, double-blind, placebo-controlled, parallel-group, international, Phase 3 study in patients with newly diagnosed H3 K27M-mutant diffuse glioma to assess whether treatment with dordaviprone (ONC201) following frontline …
Sponsor: Jazz Pharmaceuticals
NCT ID: NCT05580562
Sites in Maryland: - University of Maryland School of Medicine — Baltimore, Maryland
Phase 3 Recruiting Industry
This is a multicenter, two-arm, randomized, double-blind, placebo-controlled study of Optune® (Tumor Treating Fields at 200 kHz) together with maintenance Temozolomide (TMZ) chemotherapy agent and pembrolizumab compared to Optune® together…
Sponsor: NovoCure GmbH
NCT ID: NCT06556563
Sites in Maryland: - University of Maryland — Baltimore, Maryland
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier opening with Exablate Model 4000 Type 2.0/2.1 for the treatment of NSCLC brain metastases in patients who are undergoing planned FDA approved,…
Sponsor: InSightec
NCT ID: NCT05317858
Sites in Maryland: - University of Maryland — Baltimore, Maryland
Phase 3 Recruiting Academic/Other
This phase III trial studies the side effects and how well stereotactic radiosurgery (SRS) works before or after surgery in patients with tumors that has spread to the brain or that can be removed by surgery. Stereotactic radiosurgery is a…
Sponsor: Mayo Clinic
NCT ID: NCT03750227
Sites in Maryland: - National Institutes of Neurological Disorders and Stroke, NIH — Bethesda, Maryland
Phase 2 Recruiting Network
This phase II trial studies the best approach to combine chemotherapy and radiation therapy (RT) based on the patient's response to induction chemotherapy in patients with non-germinomatous germ cell tumors (NGGCT) that have not spread to …
Sponsor: Children's Oncology Group
NCT ID: NCT04684368
Sites in Maryland: - Sinai Hospital of Baltimore — Baltimore, Maryland
- Johns Hopkins University/Sidney Kimmel Cancer Center — Baltimore, Maryland
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors or lymphoma that has come back (relapsed) or does not respond…
Sponsor: Children's Oncology Group
NCT ID: NCT04870944
Sites in Maryland: - Johns Hopkins University/Sidney Kimmel Cancer Center — Baltimore, Maryland
Phase 2 Recruiting Industry
The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with locally advanced or metastatic solid tumors, or recurrent or progressive primary central nervous system (CNS) tumors harborin…
Sponsor: Fore Biotherapeutics
NCT ID: NCT05503797
Sites in Maryland: - The John Hopkins Hospital — Baltimore, Maryland
- Maryland Oncology Hematology- Columbia — Rockville, Maryland
Phase 2 Recruiting Academic/Other
This phase II trial determines if the combination of ONC201 with different drugs is effective for treating participants with diffuse midline gliomas (DMGs). Despite years of research, little to no progress has been made to improve outcomes…
Sponsor: University of California, San Francisco
NCT ID: NCT05009992
Sites in Maryland: - Johns Hopkins University — Baltimore, Maryland
Phase 2 Recruiting Industry
This study is a multicenter, two-stage clinical trial to evaluate the efficacy and safety of utidelone in combination with capecitabine in patients with HER2-negative breast cancer with brain metastases. Patients will be enrolled to receiv…
Sponsor: Biostar Pharma, Inc.
NCT ID: NCT06764940
Sites in Maryland: - The Johns Hopkins Sidney Kimmel Cancer Center, Johns Hopkins School of Medicine — Baltimore, Maryland
Phase 2 Recruiting Academic/Other
The purpose of this study is to evaluate the efficacy of digoxin in treating relapsed non-SHH, non-WNT medulloblastoma in pediatric and young adult patients.
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
NCT ID: NCT06701812
Sites in Maryland: - Johns Hopkins Sidney Kimmel Comprehensive Cancer Center — Baltimore, Maryland
Phase 2 Recruiting Industry
This is a Phase 2, multi center, open-label study to evaluate the safety and efficacy of Type II RAF (tovorafenib) in pediatric participants with low-grade glioma or advanced solid tumors. Qualifying genomic alterations will be identified …
Sponsor: Day One Biopharmaceuticals, Inc.
NCT ID: NCT04775485
Sites in Maryland: - Johns Hopkins Hospital — Baltimore, Maryland
Phase 2 Recruiting Academic/Other
This is a multi-arm phase II platform-basket screening study designed to test multiple experimental therapies simultaneously in patients with NF2-related schwannomatosis (NF2-SWN, formerly known as neurofibromatosis type 2) with associated…
Sponsor: Scott R. Plotkin, MD, PhD
NCT ID: NCT04374305
Sites in Maryland: - Johns Hopkins Hospital — Baltimore, Maryland
Phase 1, Phase 2 Recruiting NIH
Background: About 90,000 new cases of brain and spinal cord tumors are diagnosed annually in the United States. Most of these tumors are benign; however, about 30% are malignant, and 35% of people with malignant tumors in the brain and spi…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06161519
Sites in Maryland: - National Institutes of Health Clinical Center — Bethesda, Maryland
Phase 1 Recruiting Academic/Other
This phase I trial studies the side effects and best dose of trametinib and everolimus in treating pediatric and young adult patients with gliomas that have come back (recurrent). Trametinib acts by targeting a protein in cells called MEK …
Sponsor: University of California, San Francisco
NCT ID: NCT04485559
Sites in Maryland: - John Hopkins University — Baltimore, Maryland
Phase 1 Recruiting Industry
A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Efficacy of 212Pb-DOTAM-GRPR1 in Adult Participants with Recurrent or Metastatic …
Sponsor: Orano Med Theranostics, SAS
NCT ID: NCT05283330
Sites in Maryland: - Advanced Molecular Imaging and Therapy — Glen Burnie, Maryland
- United Theranostics - Chesapeake — Glen Burnie, Maryland
Phase 1 Recruiting Academic/Other
The purpose of the study is to evaluate the safety and survival of carmustine wafers and radiation and retifanlimab with or without temozolomide (TMZ) in newly-diagnosed adult subjects with glioblastoma multiform after carmustine wafer pla…
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT ID: NCT05083754
Sites in Maryland: - Johns Hopkins Medical Institution — Baltimore, Maryland
Phase 1 Recruiting Industry
The primary objective of this Phase 1, open-label, dose-escalation, and exploratory study is to evaluate the safety and tolerability profile (establish the maximum-tolerated dose) and evaluate the occurrence of dose-limiting toxicities (DL…
Sponsor: Jazz Pharmaceuticals
NCT ID: NCT04541082
Sites in Maryland: - National Institutes of Health — Bethesda, Maryland
EARLY Phase 1 Recruiting Academic/Other
The investigators will evaluate the sensitivity of ctDNA from plasma and CSF at baseline (defined as C1D1) and over time in response to treatment with plixorafenib alone or in combination with retifanlimab in patients with BRAF-V600E mutan…
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT ID: NCT06610682
Sites in Maryland: - Johns Hopkins — Baltimore, Maryland
NA Recruiting Industry
Randomized, post-market multi-center study investigating the efficacy of two sets of treatment algorithms in brain metastases (BM) patients at the time of first intervention for radiographic progression after stereotactic radiosurgery (SRS…
Sponsor: Monteris Medical
NCT ID: NCT05124912
Sites in Maryland: - University of Maryland — Baltimore, Maryland
Phase 4 Recruiting Industry
This study is to provide access for patients who are receiving treatment with dabrafenib and/or trametinib in a Novartis-sponsored Oncology Global Development, Global Medical Affairs or a former GSK-sponsored study who have fulfilled the r…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT03340506
Sites in Maryland: - National Institute Of Health — Bethesda, Maryland
NA Recruiting Academic/Other
The purpose of this study is to evaluate the treatment regimen of using Laser Interstitial Thermal Therapy (LITT) and Hypo-fractionated Radiation Therapy to treat patients with recurrent gliomas.
Sponsor: University of Maryland, Baltimore
NCT ID: NCT04181684
Sites in Maryland: - University of Maryland Greenebaum Cancer Center — Baltimore, Maryland
- UCH Kaufman Cancer Center — Bel Air, Maryland
- Central Maryland Radiation Oncology — Columbia, Maryland
- Baltimore Washington Medical Center — Glen Burnie, Maryland